2. Metabolic Enzyme/Protease Immunology/Inflammation
  3. Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
  4. Avanafil dibenzenesulfonate

Avanafil dibenzenesulfonate  (Synonyms: TA1790 dibenzenesulfonate)

Cat. No.: HY-18252A
Handling Instructions

Molarity Calculator

Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis.

For research use only. We do not sell to patients.

Avanafil dibenzenesulfonate Chemical Structure

Avanafil dibenzenesulfonate Chemical Structure

CAS No. : 330784-48-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Avanafil dibenzenesulfonate:

Other Forms of Avanafil dibenzenesulfonate:

Avanafil dibenzenesulfonate Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Avanafil dibenzenesulfonate

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis[1][2][3].

IC50 & Target[3]

PDE5

5.2 nM (IC50)

PDE6

630 nM (IC50)

PDE4

5700 nM (IC50)

PDE10

6200 nM (IC50)

PDE7

27000 nM (IC50)

PDE2

51000 nM (IC50)

PDE1

53000 nM (IC50)

In Vitro

Avanafil (TA-1790) dibenzenesulfonate (0.01-1000 µM) enhances by 45% for electrical field stimulation (1-20 Hz)-induced relaxation responses in corpus cavernosum strips from the diabetic group[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Avanafil dibenzenesulfonate Related Antibodies
In Vivo

Avanafil (TA-1790) dibenzenesulfonate (10 mg/kg; p.o.; daily, for 30 d; male rat) increases angiogenesis in bone tissue via the activation of NO, cGMP and PKG (NO/cGMP/PKG) signaling-pathway and significantly decreases dexamethasone-induced loss in BMD, bone atrophy, and oxidative stress[1].
Avanafil (TA-1790) dibenzenesulfonate (10 µM; ICI; once, for 10 weeks) improves erectile responses in T2DM rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male rat model of glucocorticoid-induced osteoporosis (GIOP)[1]
Dosage: 10 mg/kg
Administration: Oral administration; daily, for 30 days
Result: Decreased the level of eNOS, NO, PDE-5, PICP, MDA, CoQ10/CoQ10H and 8-OHdG/108dG. Increased the level of cGMP, PKG, Cortisol and CTCP.
Animal Model: Male rat model of glucocorticoid-induced osteoporosis (GIOP)[1]
Dosage: 10 mg/kg
Administration: Oral administration; daily, for 30 days
Result: Increased right femur trabecular bone thickness and epiphyseal bone width.
Animal Model: Male T2DM Sprague Dawley rats[2]
Dosage: 10 µM
Administration: Intracavernous injection; once, for 10 weeks
Result: Increased in ICP/MAP in response to nerve stimulation and increased total ICP values.
Clinical Trial
Molecular Weight

800.30

Formula

C35H38ClN7O9S2
CAS No.
SMILES

O=C(C1=CN=C(N2[C@H](CO)CCC2)N=C1NCC3=CC=C(OC)C(Cl)=C3)NCC4=NC=CC=N4.O=S(C5=CC=CC=C5)(O)=O.O=S(C6=CC=CC=C6)(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Avanafil dibenzenesulfonate Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Avanafil dibenzenesulfonate330784-48-0TA1790 dibenzenesulfonatePhosphodiesterase (PDE)NO SynthaseEndogenous MetaboliteNitric oxide synthasesNOSbone densitydexamethasoneosteoporosiserectile dysfunctioncorpus cavernosumInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Avanafil dibenzenesulfonate
Cat. No.:
HY-18252A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.